The Online Investor
Oncternal Therapeutics Inc (GTXI)

Oncternal Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization medicines to treat medical conditions, including stress urinary incontinence and prostate cancer. Co. is focused on the further development of selective androgen receptor modulators (SARMs), including its primary product candidate, enobosarm (GTx-024). SARMs is a class of drugs that has the potential to treat serious medical conditions such as stress urinary incontinence. Co. is also evaluating enobosarm and other compounds in its SARM portfolio for indications outside of oncology.
Company Name: 
Oncternal Therapeutics Inc
Website: 
www.gtxinc.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree GTXI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Oncternal Therapeutics Inc (GTXI) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.